%0 Journal Article %T IDH mutational status and the immune system in gliomas: a tale of two tumors? %A Choi, Bryan D. %A Curry, William T. %J Translational Cancer Research %D 2017 %B 2017 %9 %! IDH mutational status and the immune system in gliomas: a tale of two tumors? %K %X Gliomas are the most common type of primary brain tumor and include glioblastoma (GBM), which is the most lethal form of the disease, and remains a significant, unmet clinical need (1). Contrary to conventional notions of central nervous system immune-privilege, there is indeed extensive cross-talk between the immune system and tumors in the brain. Several successful immune therapies are either in development or have received recent approval from the Food and Drug Administration across a broad array of cancers ( Table 1 ). However, the results for immune therapy against solid tumors in the brain have been less dramatic to date. %U https://tcr.amegroups.org/article/view/16582 %P S1253-S1256 %@ 2219-6803